CrossBridge Bio Enters Agreement to Be Acquired by Eli Lilly to Advance Dual-Payload Antibody-Drug Conjugates
CrossBridge Bio announced it has entered into a definitive agreement to be acquired by Eli Lilly, with the deal valued at up to $300 million. The acquisition centers on CrossBridge’s next-generation dual-payload antibody-drug conjugate (ADC) platform, designed to improve cancer targeting by delivering multiple therapeutic agents directly to tumor cells. Through this transaction, Eli Lilly aims to strengthen its oncology pipeline and accelerate development of more differentiated and potentially more effective ADC-based cancer therapies. 
CrossBridge Bio Enters Agreement to Be Acquired by Eli Lilly to Advance Dual-Payload Antibody-Drug Conjugates